ABSTRACT
Sixty-one patients with healed duodenal ulcer were studied during a 12-month maintenance trial with either 150 mg ranitidine at night or 400 mg cimetidine at night. Recurrences were determined at endoscopy after 6 and 12 months of treatment or because of symptomatic relapse. Ulcers recurred in 7 of 28 patients receiving ranitidine and in 8 of 33 patients receiving cimetidine. No serious side effects were encountered.
Subject(s)
Cimetidine/therapeutic use , Duodenal Ulcer/drug therapy , Ranitidine/therapeutic use , Adolescent , Adult , Aged , Cimetidine/adverse effects , Clinical Trials as Topic , Female , Humans , Male , Middle Aged , Ranitidine/adverse effects , RecurrenceSubject(s)
Barotrauma/diagnosis , Cranial Nerve Injuries , Adult , Decompression/adverse effects , Diving/adverse effects , Humans , MaleABSTRACT
One hundred and three outpatients with endoscopically diagnosed duodenal ulcer were randomly allocated to treatment with either cimetidine 200 mg tds and 400 mg nocte, or ranitidine 150 mg bd for four weeks. The endoscopists were not aware of the treatment and took no part in the clinical management. On completion of treatment ulcers had healed in 43 of 51 (84%) patients given cimetidine and in 40 of 52 (77%) patients given ranitidine. There were no serious unwanted effects in either treatment group. The results show no significant difference between healing rates after four weeks of standard cimetidine therapy or ranitidine 150 mg bd.
